A Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of MK-0482 in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
Latest Information Update: 04 Jan 2024
At a glance
- Drugs MK 0482 (Primary)
- Indications Acute myeloid leukaemia; Acute myelomonocytic leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 26 Dec 2023 Status changed from active, no longer recruiting to discontinued.
- 03 Dec 2023 Planned End Date changed from 25 Aug 2025 to 31 Dec 2023.
- 03 Dec 2023 Planned primary completion date changed from 25 Aug 2025 to 31 Dec 2023.